Wegovy is the only semaglutide product FDA-approved specifically for weight loss. In its pivotal clinical trial, people using the 2.4 mg weekly injection lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with a placebo. While other semaglutide brands exist, including Ozempic and Rybelsus, they are approved for type 2 diabetes management, not weight loss, even though they contain the same active ingredient.
How the Three Brands Differ
Semaglutide is sold under three brand names, each with a distinct FDA-approved purpose. Wegovy is the injectable pen approved for chronic weight management. Ozempic is also an injectable pen, but it’s approved for blood sugar control in type 2 diabetes and carries a lower maximum dose (2.0 mg versus Wegovy’s 2.4 mg). Rybelsus is a daily oral tablet approved for type 2 diabetes at doses of 7 mg and 14 mg.
Doctors sometimes prescribe Ozempic off-label for weight loss because it’s the same molecule, and it does cause weight loss. But because the maximum dose is lower, and because it wasn’t tested and approved at the doses used in the large weight loss trials, Wegovy remains the standard choice when the primary goal is losing weight. Insurance coverage also often hinges on whether the prescribed product matches its approved indication.
How Much Weight People Lose on Wegovy
The STEP 1 trial, published in the New England Journal of Medicine, enrolled adults with obesity or overweight who did not have diabetes. Over 68 weeks, participants on Wegovy 2.4 mg lost an average of 14.9% of their body weight. Among those who took the medication consistently as intended, the average loss was closer to 16.9%. To put that in perspective, for someone weighing 220 pounds, that translates to roughly 33 to 37 pounds.
The results weren’t evenly distributed. Some people respond more dramatically than others. But the trial showed that about 86% of participants on Wegovy lost at least 5% of their body weight, and roughly a third lost 20% or more. Beyond weight loss, Wegovy also has a separate FDA approval for reducing the risk of heart attack, stroke, and cardiovascular death in adults with heart disease who also have obesity or overweight.
What About a Higher-Dose Oral Option?
A higher-dose oral semaglutide tablet (50 mg daily) has been tested in clinical trials for weight loss and showed impressive results. In the OASIS 1 trial, participants taking the 50 mg oral dose lost an average of 15.1% of their body weight over 68 weeks, putting it in a similar range to the injectable Wegovy. About 85% of participants lost at least 5% of their weight, and 54% lost 15% or more.
This higher oral dose is not yet available as an approved product for weight loss. The currently available oral semaglutide, Rybelsus, tops out at 14 mg and is approved only for diabetes. If the 50 mg tablet eventually reaches the market, it could offer a needle-free alternative with comparable results, but for now, Wegovy remains the only approved option.
How Semaglutide Causes Weight Loss
Semaglutide mimics a gut hormone called GLP-1 that your body naturally releases after eating. It works through two main pathways. In the brain, it acts on the hypothalamus, the region that regulates hunger and energy balance. It activates neurons that promote feelings of fullness while simultaneously quieting the neurons that drive appetite. The net effect is that food becomes less mentally preoccupying, portions feel more satisfying, and cravings diminish.
In the gut, semaglutide slows the rate at which your stomach empties after a meal. This keeps you feeling full longer and reduces the urge to eat again soon after. Together, these effects lead to a sustained reduction in calorie intake without requiring constant willpower. Most people describe it as simply not thinking about food as much.
The Dosing Schedule
Wegovy isn’t started at the full dose. You begin at 0.25 mg once a week, and the dose increases every four weeks through five steps: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg. This gradual ramp-up takes about 16 to 20 weeks and exists to reduce side effects, particularly nausea. Some people settle at the 1.7 mg maintenance dose if 2.4 mg isn’t tolerated well.
Each dose comes in a separate prefilled pen. The injection is subcutaneous, typically in the abdomen, thigh, or upper arm, and uses a small needle similar to insulin pens. Most people find the weekly injection routine straightforward once they’ve done it a few times.
Side Effects to Expect
Gastrointestinal side effects are the most common issue and the primary reason some people stop treatment. Across the clinical trials for the 2.4 mg dose, about 44% of participants experienced nausea, 30% had diarrhea, 25% had vomiting, and 24% reported constipation. These numbers are considerably higher than placebo rates.
The good news is that these effects are typically worst during the dose escalation phase and tend to improve as your body adjusts. Eating smaller meals, avoiding high-fat foods, and staying hydrated can help. Most nausea is mild to moderate, not the severe kind that keeps you in bed, though a small percentage of people do find it intolerable enough to discontinue.
Who Qualifies for Wegovy
The FDA-approved criteria require a BMI of 30 or higher (obesity), or a BMI of 27 or higher (overweight) with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. For adolescents aged 12 and older, the threshold is a BMI at or above the 95th percentile for their age and sex. In all cases, Wegovy is meant to be used alongside a reduced-calorie diet and increased physical activity, not as a standalone solution.
Why Compounded Semaglutide Is Risky
With brand-name semaglutide costing around $1,000 or more per month at list price, many people have turned to compounded versions from specialty pharmacies. The FDA has raised serious concerns about this. Compounded semaglutide is not FDA-reviewed for safety, effectiveness, or quality. As of July 2025, the FDA had received 605 reports of adverse events linked to compounded semaglutide, some requiring hospitalization.
Several specific problems have emerged. Some compounded products use salt forms of semaglutide (like semaglutide sodium or semaglutide acetate) that are chemically different from the active ingredient in approved products. The FDA has stated it has no evidence these salts behave the same way in the body. Reports also include dosing errors from compounded injectables, products arriving without proper refrigeration, and fraudulent labeling. The cost savings may be tempting, but the tradeoff involves real and documented safety risks.
Cost and Insurance Coverage
List prices for both Wegovy and Ozempic remain around $1,000 or more per month, though Novo Nordisk has recently introduced price reductions. What you actually pay depends heavily on your insurance plan. Many commercial insurers now cover Wegovy for weight loss, though prior authorization is common and approval often requires documentation of BMI, previous weight loss attempts, and qualifying health conditions. Some plans still exclude weight loss medications entirely.
Manufacturer savings programs can bring the out-of-pocket cost down significantly for commercially insured patients. For those without coverage, the full cash price makes long-term use prohibitive for most people, which is one reason off-label Ozempic use and compounded alternatives have become so widespread despite the limitations and risks involved.